TScan Therapeutics, Inc.
TCRXTScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer and autoimmune disorders.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer and autoimmune disorders. The company utilizes a proprietary target discovery platform to identify novel antigens and naturally occurring TCRs to create therapies that mimic the immune system's natural response. Its primary focus is on hematologic malignancies and solid tumors, supported by in-house GMP manufacturing and a non-viral gene delivery system.
A clinical-stage innovator in the TCR-T space with a unique focus on post-transplant relapse prevention and a proprietary non-viral manufacturing platform.
Questions, answered.
- What is TScan Therapeutics, Inc.'s market cap?
- TScan Therapeutics, Inc. (TCRX) has a market capitalization of $50.2M and trades on NASDAQ.
- Who are TScan Therapeutics, Inc.'s competitors?
- TScan Therapeutics, Inc.'s key competitors include IN8bio, Inc., Immatics N.V., Iovance Biotherapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does TScan Therapeutics, Inc. partner with?
- TScan Therapeutics, Inc.'s notable partners include Amgen Inc., The Brigham and Women's Hospital, Inc., Provincial Health Services Authority, and others.
- Where is TScan Therapeutics, Inc. headquartered?
- TScan Therapeutics, Inc. is headquartered in United States of America and employs approximately 154 people. It has been publicly traded since 2021.